Edition:
United Kingdom

AMAG Pharmaceuticals Inc (AMAG.OQ)

AMAG.OQ on NASDAQ Stock Exchange Global Select Market

18.50USD
16 Feb 2018
Change (% chg)

$0.55 (+3.06%)
Prev Close
$17.95
Open
$17.85
Day's High
$18.55
Day's Low
$17.65
Volume
638,472
Avg. Vol
229,753
52-wk High
$25.15
52-wk Low
$11.93

Chart for

About

AMAG Pharmaceuticals, Inc. is a pharmaceutical company. The Company's segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia... (more)

Overall

Beta: 0.91
Market Cap(Mil.): $661.66
Shares Outstanding(Mil.): 35.29
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.64
EPS (TTM): -- -- --
ROI: -- 14.90 10.66
ROE: -- 16.41 14.30

BRIEF-AMAG Gets FDA Approval Of Makena Subcutaneous Auto-Injector

* AMAG PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF MAKENA® (HYDROXYPROGESTERONE CAPROATE INJECTION) SUBCUTANEOUS AUTO-INJECTOR TO REDUCE THE RISK OF PRETERM BIRTH IN CERTAIN AT-RISK WOMEN

14 Feb 2018

BRIEF-AMAG Pharmaceuticals Announces FDA Approval Of Supplemental New Drug Application (SNDA) For Feraheme

* AMAG PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) FOR FERAHEME® (FERUMOXYTOL INJECTION) Source text for Eikon: Further company coverage:

05 Feb 2018

BRIEF-AMAG Pharmaceuticals Sees Q4 2017 Revenue $156 Mln to $163 Mln

* AMAG PHARMACEUTICALS ANNOUNCES PRELIMINARY 2017 FINANCIAL RESULTS AND PROVIDES 2018 GUIDANCE

08 Jan 2018

UPDATE 1-Around 6,000 Swiss VW owners seek damages in emissions scandal

* VW says 98 percent of affected vehicles already fixed (Adds VW reaction)

30 Dec 2017

BRIEF-New Patent Issued To Amag Pharmaceuticals Entitled "Methods Of Reducing Risk Of Preterm Birth"

* NEW PATENT ISSUED TO AMAG PHARMACEUTICALS ENTITLED "METHODS OF REDUCING RISK OF PRETERM BIRTH" Source text for Eikon: Further company coverage:

20 Dec 2017

BRIEF-Amag Pharmaceuticals Q3 loss per share $4.31

* Amag Pharmaceuticals announces third quarter 2017 financial results and business highlights

02 Nov 2017

BRIEF-Amag Pharmaceuticals announces U.S. FDA filing acceptance

* Amag announces U.S. FDA filing acceptance and six-month review of Feraheme® (Ferumoxytol) for the treatment of all adult patients with iron deficiency anemia

31 Aug 2017

Earnings vs. Estimates